|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 31/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3532098 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17797564.6 |
| Date of filing the European patent application | 2017-10-27 | |
| (97) | Date of publication of the European application | 2019-09-04 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-07 |
| (46) | Date of publication of the claims translation | 2021-06-25 |
| (86) | Number | PCT/EP2017/077654 |
| Date | 2017-10-27 |
| (87) | Number | WO 2018/078123 |
| Date | 2018-05-03 |
| (30) | Number | Date | Country code |
| 16196184 | 2016-10-28 | EP |
| (72) |
ENDELL, Jan, DE
PETROPOULOS, Konstantin, DE
KELEMEN, Peter, DE
BOXHAMMER, Rainer, DE
RÜCKERT, Markus, DE
|
| (73) |
Incyte Corporation ,
1801 Augustine Cut-Off, Wilmington, Delaware 19803,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti CD19 antikūno derinys su BCL-2 inhibitoriumi, ir jo naudojimas |
| COMBINATION OF ANTI CD19 ANTIBODY WITH A BCL-2 INHIBITOR AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-10-03 | 9 | 208.00 EUR |
| 2026-10-27 |